Small molecule inhibition of stat3 enhances survival in mice with intracerebral melanoma

Melanoma is a common and deadly tumor that upon metastasis to the brain, survival is less than one year. Development of new, effective therapies for metastatic melanoma that target novel pathways associated with the genesis of metastatic disease is a major unmet clinical need. Constitutive activation of STAT3 has been demonstrated in a variety of human malignancies, including melanoma. We have designed and synthesized a series of potential inhibitors of the JAK2/STAT3 pathway and identified a lead compound displaying high activity within in vivo models. In the study described here, we tested that in mouse models WP1066, a novel STAT3 pathway blockade agent, has marked in vitro and in vivo activity, even with metastasis to the brain, a site typically refractory to therapies. WP1066 achieved an IC50 of 1.6 μM, 2.3 μM, and 1.5 μM against the human melanoma cell line A375, murine melanoma cell line B16, and B16EGFRvIII, respectively. WP1066 suppressed the phosphorylation of JAK2 and phosphorylation (Tyr705) of STAT3 in all three melanoma cell lines. In addition, WP1066 decreased the level of c-Myc and survivin in melanoma cells in a dose- and time-dependent manner. Subcutaneous tumor growth of B16EGFRvIII and B16 in a syngeneic murine model in the C57BL/6J background was markedly inhibited by WP1066 compared to those in the vehicle control group (P<0.05). Long-term survival was observed in 80% of mice with established intracerebral syngeneic melanoma treated with 40 mg/kg of WP1066 in contrast to mice treated with the vehicle control that had a median survival of 15 days (P<0.001). Upon rechallenge, in the animal group that had received WP1066 via o.g., the median survival was 18 days (95% CI: 17, NA), which was significantly different compared to naïve animals challenged at the same time that had a median survival of 11 days (95% CI; 10, NA) (p